PCSK9 and atherosclerosis: To prove the clinical benefit of inclisiran, the ORION-4 trial will assess whether PCSK9 silencing safely lowers the risk of major atherosclerotic cardiovascular events in ≥ 15,000 patients with pre-existing ASCVD during a median treatment duration of 5 years (NCT03705234).